Inclusion Criteria:

          1. Has a history of surgically resected and pathologically proved AJCC stage I or stage
             II adenocarcinoma of the head, neck, or uncinate of the pancreas.

          2. Has been a participant in Hopkins IRB protocol (J0810) application number 00-01-58-58
             entitled, "A randomized three-arm neoadjuvant and adjuvant feasibility and toxicity
             study of a GM-CSF secreting allogeneic pancreatic cancer vaccine administered either
             alone or in combination with either a single intravenous dose or daily metronomic oral
             doses of cyclophosphamide for treatment of patients with surgically resected
             adenocarcinoma of the pancreas"( the J0810 cohort), or have never received any type of
             pancreatic cancer vaccine/immunotherapy, had the Whipple surgery within 18 months and
             completed the planned adjuvant chemotherapy and /or chemoradiation (the vaccine naive
             cohort).

          3. Has provided informed consent.

          4. Has received the last irradiated GM-CSF transfected allogeneic pancreatic cell lines
             Panc 10/05/Panc 6.03 at least six months prior (+/- 1 month).Not applicable to the
             vaccine-naive cohort patients.

          5. Has received the last anti-cancer therapy at least 28 days ago.

          6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          7. Has adequate hematologic function.(Hemoglobin ≥ 9 g/dL ANC ≥ 1500/mm3 Platelets ≥
             100,000 K/ mm3).

          8. Has adequate renal function? (Serum creatinine ≤ 2 mg/dL).

          9. Has adequate hepatic function. (Bilirubin ≤ 2.0 mg/dl, unless known Gilbert's
             Syndrome; AST, ALT and amylase ≤ 2x upper limit of normal, Alk Phos ≤ 5x upper limit
             of normal).

         10. Agree to use adequate birth control, if of childbearing potential.

        Exclusion Criteria:

          1. Has radiographic evidence of pancreatic cancer recurrence.

          2. Has any documented history of autoimmune diseases including systemic lupus
             erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis,or vasculitis.

          3. Has any uncontrolled medical problems.

          4. Has had systemic steroid therapy within 28 days before vaccine administration.

          5. Has an anticipated need for systemic steroid therapy within 28 days after vaccine
             administration.

          6. Has any evidence of active infections.

          7. Is pregnant.

          8. Has a history of another cancer (other than pancreatic cancer) or myeloproliferative
             disorders in the past five years except for treated non-melanoma skin cancer,
             superficial bladder cancer, or carcinoma in-situ of the cervix.

          9. Has a history of noncompliance during previous vaccination cycles with study treatment
             and/or monitoring which is concerning for continued noncompliance.